Skip to main content

Peripheral Neuropathy and cannabis in Alabama

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Physician-certified med…
POSSESSION
$65/yr
STATE FEE
7–30 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Alabama statute and program

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) is the operating authority for Alabama patient certification. The authoritative legal text is: Alabama Compassion Act (SB 46 of 2021).

What the evidence says about cannabis and Peripheral Neuropathy

Peripheral neuropathy is damage to or dysfunction of the peripheral nervous system (nerves outside the brain and spinal cord). Common causes include diabetes mellitus, chemotherapy, HIV infection, alcohol use, autoimmune disease, vitamin deficiency, infection, trauma, and inherited disorders. Symptoms typically include burning or shooting pain, tingling, numbness, weakness, and loss of coordination, most often in a stocking-glove distribution affecting feet first and then hands.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Peripheral Neuropathy page.

How to qualify in Alabama

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) requires the following registration steps for a Peripheral Neuropathy patient (or any qualifying diagnosis):

  1. See an Alabama-licensed certifying physician. Under the Darren Wesley "Ato" Hall Compassion Act (Alabama Act 2021-450), only physicians who have completed the four-hour Alabama Medical Cannabis Commission (AMCC) certification course and registered with the AMCC may certify patients. The physician evaluates the patient for one of the enumerated qualifying conditions (autism, cancer-related cachexia or chronic pain, Crohn’s, depression, epilepsy, HIV/AIDS, panic disorder, Parkinson’s, PTSD, sickle-cell, intractable pain, terminal illness, and others under §20-2A-3).
  2. Register through the AMCC patient portal. After certification, the patient creates an account in the AMCC patient registry using a current Alabama driver license or state ID. The physician’s certification is linked electronically to the patient’s record. Caregivers (required for minor patients) register separately and pass a state and federal background check.
  3. Pay the $65 state registration fee. The annual AMCC patient registration fee is $65 (caregiver registration is also $65). Once paid, the patient receives a digital medical cannabis card. The program does not yet have brick-and-mortar dispensaries open as of the program’s phased launch — operating dispensary licenses were issued in 2024 with retail expected to begin in 2025.
  4. Purchase from an AMCC-licensed dispensary. With the digital card and Alabama ID, patients may purchase Alabama-permitted forms (tablets, capsules, tinctures, gels, oils, gummies, lozenges, suppositories, topical patches, transdermal patches, nebulizers, and liquids or oils for use in an inhaler — no smokable flower, edibles intended to look like candy, or vaping products under §20-2A-3(15)). Adult-use cannabis remains illegal in Alabama.
State registration fee
$65
Physician visit (typical)
$200–$400
Certification to card
7–30 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Alabama registration steps, fees, and reciprocity rules, see the Alabama cannabis-laws page.

ICD-10 code

A certifying physician documenting Peripheral Neuropathy for the Alabama medical cannabis program will typically record ICD-10 G62.9 or SNOMED-CT 42658009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Alabama list Peripheral Neuropathy as a qualifying condition for medical cannabis?

No. Alabama's qualifying-condition list does not currently include Peripheral Neuropathy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Peripheral Neuropathy in Alabama have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Alabama program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Alabama medical marijuana card for Peripheral Neuropathy?

Because Alabama does not currently list Peripheral Neuropathy as a qualifying condition, a card for Peripheral Neuropathy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Alabama who is registered with Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) and willing to evaluate Peripheral Neuropathy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Alabama does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Peripheral Neuropathy?

For Peripheral Neuropathy, evidence is described as moderate (supportive controlled studies exist but the picture is mixed). The mmjnow condition page for Peripheral Neuropathy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Peripheral Neuropathy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Peripheral Neuropathy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Peripheral Neuropathy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Alabama Compassion Act (SB 46 of 2021)accessed May 16, 2026
  2. Alabama Medical Cannabis Commissionaccessed May 16, 2026
  3. Wikipedia: Cannabis in Alabamaaccessed May 16, 2026
  4. Ala. Code §13A-12-214: Unlawful possession of marijuana (penalty schedule)accessed May 17, 2026
  5. Alabama SB 46 (2021): Darren Wesley 'Ato' Hall Compassion Actaccessed May 17, 2026
  6. Alabama Department of Agriculture & Industries: Industrial Hemp Programaccessed May 17, 2026
  7. Alabama Legislature bill trackeraccessed May 17, 2026
  8. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 16, 2026

    “Substantial evidence that cannabis is an effective treatment for chronic pain in adults.”

  9. NIH NINDS: Peripheral Neuropathyaccessed May 16, 2026